Table 3.

Results of OS and RFS.

Outcomes	No. Of studies	1 year	2 years	3 years
OS
PD-(L)1 inhibitors alone	2	91.7%	84.85%	80.28%
PD-(L)1 inhibitors plus other ICI	1	96.05%	96.05%	96.05%
PD-(L)1 inhibitors plus chemotherapy	2	92.11%	80.07%	80.07%
Neoadjuvant PD-(L)1 inhibitors	5	91.67%	86.03%	81.64%
RFS
PD-(L)1 inhibitors alone	2	85.3%	80.12%	79.3%
PD-(L)1 inhibitors plus other ICI	1	91.72%	91.72%	91.72%
PD-(L)1 inhibitors plus chemotherapy	3	84.47%	71.84%	71.84%
Neoadjuvant PD-(L)1 inhibitors	6	85.69%	79.67%	79.05%